Latest & greatest articles for Stimulant Use Disorder

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Stimulant Use Disorder or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Stimulant Use Disorder and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Stimulant Use Disorder

1. Pharmacotherapy for Stimulant Use Disorders

Pharmacotherapy for Stimulant Use Disorders Management Briefs eBrief-no147 -- Pharmacotherapy for Stimulant Use Disorders Enter search terms Button to search HSRD ® Inside VA Budget and Performance Inside the News Room National Observances Special Events » » » » » Management Briefs eBrief-no147 -- Pharmacotherapy for Stimulant Use Disorders Health Services Research & Development Management eBrief no. 147 » Issue 147 October 2018 The report is a product of the VA/HSR&D Evidence Synthesis Program (...) . Pharmacotherapy for Stimulant Use Disorders: A Systematic Review Stimulant use disorders, specifically cocaine and methamphetamine use disorders, present ongoing public health problems in the United States, with major medical, psychiatric, cognitive, socioeconomic, and legal consequences. There are more emergency department visits associated with cocaine compared with other illicit substances, and several US cities consider methamphetamine as the drug of abuse associated with the "most serious consequences

2018 Veterans Affairs - R&D

2. Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling? Full Text available with Trip Pro

Diagnoses of Cardiovascular Disease or Substance Addiction/Abuse in US Adults Treated for ADHD with Stimulants or Atomoxetine: Is Use Consistent with Product Labeling? Among US adults, utilization of pharmacotherapy for attention-deficit hyperactivity disorder (ADHD) has increased more than ninefold since 1995-1996. Potential contraindications to ADHD pharmacotherapy include serious cardiovascular disease (CVD) and, for stimulants, addictions and bipolar disorder (BPD).To assess the prevalence (...) of potential contraindications among adults treated with ADHD pharmacotherapy.A retrospective cohort analysis was performed using the Truven Health MarketScan® database. Subjects filled ≥ 1 prescription for atomoxetine or ≥ 1 stimulant in 2014-2015, were aged 18-64 years, commercially insured throughout observation, and diagnosed with ADHD on two or more medical claims. Diagnoses and medical procedures were measured in the 12 months prior to pharmacotherapy initiation. Metrics included serious CVD

2018 Drugs - real world outcomes

3. Systematic review with meta-analysis: Stimulant medication for ADHD not associated with subsequent substance use disorders

Systematic review with meta-analysis: Stimulant medication for ADHD not associated with subsequent substance use disorders Stimulant medication for ADHD not associated with subsequent substance use disorders | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Stimulant medication for ADHD not associated with subsequent substance use disorders Article Text Aetiology Systematic review with meta-analysis Stimulant medication for ADHD

2014 Evidence-Based Medicine

4. Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis Full Text available with Trip Pro

Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis Historical clinical (...) and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis Naci H, de Lissovoy G, Hollenbeak C, Custer B, Hofmann A, McClellan W, Gitlin M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed

2012 NHS Economic Evaluation Database.

5. Therapeutic use of Transcutaneous Electrical Nerve Stimulators for Temporomandibular Joint Disorder pain relief

Therapeutic use of Transcutaneous Electrical Nerve Stimulators for Temporomandibular Joint Disorder pain relief UTCAT809, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Therapeutic Use Of Transcutaneous Electrical Nerve Stimulators For Temporomandibular Joint Disorder Pain Relief Clinical Question In a 40 year old female with chronic TMD, does TENS (Transcutaneous Electrical Nerve Stimulators) provide better symptom (...) . There have not been enough stringent studies with a comparison using a gold standard. Therefore, at this time it would be difficult to make any conclusions as to the efficacy of TENS in TMD related illness. Evidence Search Search temporomandibular joint disorder pain management Limits: Humans, Randomized Controlled Trial, EnglishSearch temporomandibular joint disorder pain management Limits: Humans, Meta-Analysis, EnglishSearch temporomandibular joint disorder alternative treatment Limits: Humans, Meta

2011 UTHSCSA Dental School CAT Library

6. Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. Full Text available with Trip Pro

Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. To compare the effectiveness of an electrocautery strategy with ovulation induction using recombinant follicle stimulating hormone in patients with polycystic ovary syndrome.Randomised controlled trial.Secondary and tertiary hospitals in the Netherlands.168 patients with clomiphene citrate resistant polycystic ovary syndrome: 83 were (...) allocated electrocautery and 85 were allocated recombinant follicle stimulating hormone.Laparoscopic electrocautery of the ovaries followed by clomiphene citrate and recombinant follicle stimulating hormone if anovulation persisted, or induction of ovulation with recombinant follicle stimulating hormone.Ongoing pregnancy within 12 months.. The cumulative rate of ongoing pregnancy after recombinant follicle stimulating hormone was 67%. With only electrocautery it was 34%, which increased to 49% after

2004 BMJ Controlled trial quality: predicted high

7. Spinal cord stimulation: use in patients with complex regional pain syndrome

Spinal cord stimulation: use in patients with complex regional pain syndrome Spinal cord stimulation: use in patients with complex regional pain syndrome Spinal cord stimulation: use in patients with complex regional pain syndrome WCB Evidence Based Practice Group Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation WCB Evidence Based Practice Group. Spinal cord (...) stimulation: use in patients with complex regional pain syndrome. Richmond, BC: WorkSafe BC 2003: 26 Authors' objectives This study examines spinal cord stimulation and its use in patients with complex regional pain syndrome. Authors' conclusions MEDICAL EVIDENCE - CONCLUSIONS 1. Twenty-five workers have had spinal cord stimulation (SCS) implantation approved by the WCB up to October 17, 2002. Thirteen of these had complex regional pain syndrome (CRPS), while twelve workers had other diagnoses

2003 Health Technology Assessment (HTA) Database.